Haisle GeneTech and Thermo Fisher Strengthen Strategic Collaboration to Advance Infectious Pathogen Detection

Suzhou, September 5, 2019 /PRNewswire/ -- On the afternoon of August 30, 2019, at 14:00, Ningbo Health Gene Technologies Co., Ltd. (hereinafter referred to as "Health Gene Technologies") and Thermo Fisher Scientific (hereinafter referred to as "Thermo Fisher"), the world leader in serving science, held a product launch event and announced a strategic partnership at the Suzhou International Expo Center. Under this strategic agreement, both parties will engage in in-depth cooperation across multiple areas of molecular diagnostics, including clinical research, collaborative technology development, product registration and certification, sales collaboration, and brand and academic promotion. Together, they aim to establish a "Joint Innovation Laboratory" to advance the integrated precision diagnosis and treatment of infectious diseases.

Mr. Yu Ding, General Manager of Ningbo Health Gene Technologies Co., Ltd., delivered the welcome address and reviewed the company’s recent development status. Among the highlights, the pathogen precision diagnostics product series once again drew significant attention from attendees. This series comprises multiplex assay kits developed based on Amplicon Fragment Analysis (AFA) technology using capillary electrophoresis platforms. The technology features single-tube multiplexing, high-throughput detection, and integrated automated analysis software.

Dr. Xu Zhi from the Clinical Marketing Department of Ningbo Health Gene Technologies Co., Ltd. introduced to the audience multiplex detection kits for HPV E6/E7 DNA genotyping and respiratory pathogens. He stated that Ningbo Health Gene Technologies will successively launch multiplex pathogen detection kits for encephalitis and meningitis pathogens, as well as multiplex detection reagents targeting tumors and personalized medication. Through this collaboration, Ningbo Health Gene Technologies will provide the market with more comprehensive integrated solutions.

As a global leader in the field of scientific services, Thermo Fisher Scientific offers the Sanger sequencing instrument (3500Dx Genetic Analyzer), which is considered the gold standard for genetic testing. Its fragment analysis capability is a widely used genetic analysis technique, suitable for mutation detection, genotyping, DNA profiling, genetic lineage mapping, and linkage analysis. Thermo Fisher Scientific also closely monitors advancements in medical applications such as infectious diseases and pharmacogenomics. By integrating Ningbo Health Gene Technologies' molecular testing solutions for infectious pathogen detection and personalized medication guidance, the two companies are jointly pioneering a new era of precision medicine for infectious diseases.

Thermo Fisher Scientific China President, Alex Eder (Tony Acciarito) Mr. [Name] stated, “As a global leader in the scientific services industry, Thermo Fisher Scientific has consistently upheld its commitment to ‘Rooted in China, Serving China,’ striving to provide tailored solutions that meet the needs of local Chinese customers. We look forward to forming a strategic alliance with Ningbo Health Gene Technologies Co., Ltd., collaborating across multiple dimensions—including achievement transformation, standard establishment, and efficiency enhancement—to jointly pioneer a new era in precision medicine for infectious diseases.”

Thermo Fisher Scientific and Ningbo Health Gene Technologies Have a Long-Standing Partnership in the Life Sciences Sector. Building on their previously established strong relationship, the two parties are once again joining forces. This collaboration is poised to drive the translation of more independent innovative technologies into applications within China’s precision medicine and clinical testing sectors, provide higher-quality solutions and services for clinical diagnostic challenges, advance the development of precision medicine, and contribute to the “Healthy China” initiative.2030”。